Dexamethasone, an exogenous glucocorticoid upstream of AnxA1, [8] has, in fact, been shown to alter type I interferon active neutrophils in COVID-19 and improve outcomes for patients with severe COVID-19 [9,10]. This evidence concerns the gene ANXA1 and COVID-19.